Approvals for medical devices may ease with new classification

The Central Drugs Standard Control Organisation’s (CDSCO’s) draft rules for re-classification of medical devices based on their risk profile has received wide support from the industry, as it will allow cetralaised, faster approval of high-risk equipment. The classification of medical devices are done at the state and central level based on the risk profile of the devices. For instance, the manufacturing of class A and B devices, which have lower risks involved, are cleared by the state governments. The production of class C and D devices are cleared by central agency CDSCO.

Prior to this draft, the classification of the devices were left to the discretion of the state governments, especially in cases of new non-classified devices. “In some cases, the companies have to face issues with state governments because their interpretation of the risk were different from the device manufacturers. Now, that ambiguity has been addressed to a large extent. It would reduce the delays in new product launches,” said head of medical device association, on condition of anonymity.

Experts said that the classification would be more beneficial for manufacturers than importers because the importers are already taking approval from CDSCO – where they have “strong inroads – for all kinds of devices.

Rajiv Nath, forum coordinator at association of Indian medical device industry (AiMeD) said that there’s an urgent need to create awareness about this classification. “We urge constant conferences and meetings with stakeholders to bring clarity for regulatory compliance needs and alignment as we find huge variances of interpretation of medical device rules between various state and central government regulators as manufacturers wade through a daunting maze of lengthy regulatory approval hurdles so that regulatory approvals can be expedited,” he said.

Experts said that there’s a need to constantly update the list so that its purpose doesn’t get defeated. For instance, if a product classification is not known, the manufacturer would not be able to submit its applications, and it will cause delays till the CDSCO is approached, and informed about the classification based on other jurisdictions like the US, EU or Singapore.

Related Posts

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Sarvesh Singh, Director and CEO of Telangana Lifesciences and Pharma, called on industry leaders at a CII Telangana conference to embed safety by design into manufacturing culture, deploying AI, IoT,…

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Amidst tariff tensions with the US, Europe has created a major opportunity for the Indian pharmaceutical industry. The CDSCO has granted approval to three Indian companies to export APIs to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Researchers discover a compound that can boost ageing muscle repair

Researchers discover a compound that can boost ageing muscle repair

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks